InvestorsHub Logo
Followers 655
Posts 19147
Boards Moderated 5
Alias Born 07/03/2011

Re: JJJ54 post# 328

Friday, 08/12/2022 8:58:00 AM

Friday, August 12, 2022 8:58:00 AM

Post# of 335
The company said it received feedback from the FDA on information needed to resolve CTI-1601's current clinical hold, as well as a proposed change for a second phase. CTI-1601 is a treatment for Friedreich's ataxia.

Larimer plans to submit a complete response to CTI-1601's clinical hold in the third quarter.

Larimar is also proposing a phase two, four-week dose exploration study in Friedreich's ataxia patients. Friedreich's ataxia is a rare disease that causes progressive nervous system damage and movement problems, usually beginning during childhood.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LRMR News